Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Top Cited Papers
- 6 February 2003
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (6) , 538-549
- https://doi.org/10.1056/nejmra020526
Abstract
It is well recognized that different patients respond in different ways to the same medication. These differences are often greater among members of a population than they are within the same person at different times (or between monozygotic twins).1 The existence of large population differences with small intrapatient variability is consistent with inheritance as a determinant of drug response; it is estimated that genetics can account for 20 to 95 percent of variability in drug disposition and effects.2 Although many nongenetic factors influence the effects of medications, including age, organ function, concomitant therapy, drug interactions, and the nature of the disease, there are now numerous examples of cases in which interindividual differences in drug response are due to sequence variants in genes encoding drug-metabolizing enzymes, drug transporters, or drug targets.3-5 Unlike other factors influencing drug response, inherited determinants generally remain stable throughout a person's lifetime.Keywords
This publication has 92 references indexed in Scilit:
- Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug ResponseAnnual Review of Genomics and Human Genetics, 2001
- Pharmacogenomics: Unlocking the Human Genome for Better Drug TherapyAnnual Review of Pharmacology and Toxicology, 2001
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug researchPharmacogenetics, 1998
- Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine IntoleranceAnnals of Internal Medicine, 1997
- Pharmacogenetic perspectives gained from twin and family studiesPharmacology & Therapeutics, 1989
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960
- FAMILIAL INCIDENCE OF LOW PSEUDOCHOLINESTERASE LEVELThe Lancet, 1956
- Space-Time Relationships in Somesthetic LocalizationScience, 1956